Summary Members of the transforming growth factor ,B (TGF-fl family, in particular TGF-,B1, are some of the most potent inhibitory growth factors in a variety of cell types. Resistance to TGF-f,l-induced growth inhibition is frequently observed in colorectal carcinomas and is associated with tumour progression. Perturbations of TGF-,B1 expression and function, therefore, may contribute to the loss of some constraints on tumour cell growth. In this study we have examined the expression of TGF-f,l and its precursor latencyassociated peptide (LAP)-TGF-f, in human colorectal tumours using immunohistochemical techniques. In 86% of the tumours the LAP-TGF-,B complex was present in both the stromal and epithelial cells, whereas the mature TGF-fll peptide was expressed in the glandular epithelium of 58.3% of these tumours. Intense staining for TGF-,B1 was positively associated with advanced Dukes' stage. Furthermore, there was a significant correlation between the presence of TGF-f,l in the tumours and a shorter post-operative survival. This was most significant in a subgroup of patients who had received only a palliative operation. These results suggest that TGF-,B1 expression may be useful as an independent prognostic indicator for a subgroup of patients who have a particularly poor prognosis.
Colorectal cancer remains a major cause of mortality in Britain and although resectional surgery is the mainstay of treatment, 60% of patients still die within 5 years as a result of distant metastasis or local recurrence (Schofield et al., 1986) . While adjuvant radio-and chemo-therapy have improved recurrence-free survival (O'Connell and Gunderson, 1992; Wolmark et al., 1993; Kohnewompner et al., 1994; Schmoll, 1994) , these combinations fail to have a significant effect either in those patients who present with Dukes' stage B disease, or on overall patient survival. Since only a minority of patients benefit from the adjuvant treatment modalities, better selection of those at high risk of recurrence, who would gain the major benefits from adjuvant treatment is required.
Surgical and pathological staging can identify groups of colorectal cancer patients likely to be at a higher risk of tumour relapse and death (Rothenberger, 1993) . However, it is clear that even within these groups, there are subsets of patients with a better or worse prognosis than the group as a whole. The need to identify these subsets of patients has led to the measurement of numerous other variables such as DNA content (Jass et al., 1989) , proliferative index and the tumour doubling time (Khan et al., 1988) , which have been related to patient outcome. It is now clear that these factors are little better than the conventional pathological staging procedures.
The transforming growth factor # (TGF-f) gene superfamily consists of several polypeptide isoforms, of which TGF-f,l is the most abundant (reviewed in Massague et al., 1992; Lahm and Odartchenko, 1993) . TGF-fs are secreted as latent high molecular weight complexes comprising the latent TGF-,B binding protein (LTBP), the latency-associated peptide (LAP) and the mature TGF-,B peptide (reviewed in Harpel et al., 1992) . The LTBP is thought to be an important molecule for the correct assembly and secretion of TGF-il. Once secreted, TGF-,Bl remains inactive in a non-covalent association with LAP, in what has been termed the 'small latent complex'. Activation occurs via the proteolytic cleavage of the mature peptide from this complex (Odekon et al., 1994) , although the ability of LAP to reassociate with TGF-#J1 is important in regulating its availability (Wakefield et al., 1989) . In its active form, TGF-f11 inhibits the growth of epithelial cells but stimulates mesenchymal cell proliferation and cell migration (reviewed in Massague et al., 1992) . In the colon, TGF-,B appears to arrest proliferation of enterocytes as they leave the intestinal crypt and move to the villus tip. Indeed, TGF-,B immunoreactivity, which is restricted largely to the epithelial cells of human colonic crypts, is maximal in the upper regions of the crypts compared with cells in the proliferative compartment (Avery et al., 1993) , supporting the concept of TGF-f as a feature of the differentiated phenotype. Immunoreactivity was present in normal large bowel mucosa as well as colorectal carcinomas and adenomas (Avery et al., 1993) , which offers no explanation for the observation that the loss of responsiveness to the inhibitory effects of TGF-f,l in human colonic epithelial cell lines, is related to the degree of malignancy of the cells (Manning et al., 1991) . It is interesting, however, that the first report of TGF-# immunoreactivity, made in thyroid epithelium (Jasani et al., 1990) , demonstrated positive staining in malignant but not in benign or normal tissues. In addition, data from clinical studies have positively associated TGF-#l expression in vivo with the increased invasiveness in breast (Osamura et al., 1990; Gorsch et al., 1992) and prostate cancer (Steiner and Barrack, 1992; Thompson et al., 1992) and reduced survival in pancreatic carcinomas (Friess et al., 1993) .
In order to determine whether TGF-fJ1 expression could be of prognostic value in colorectal cancer we have examined the relationship between the expression of both the TGF-fB1 peptide and LAP-TGF-31 in colorectal tumours, other known prognostic indicators and patient survival. TGF-f1 was overexpressed in a group of patients with a particularly poor prognosis and was associated with a reduced survival. We suggest that TGF-,ll may be a useful prognostic indicator for the selection of patients who would benefit from more aggressive adjuvant treatments. Samples of tissue, taken as soon as the operative or biopsy specimens became available, were fixed overnight in 4% formalin and then paraffin embedded for immunohistochemical analysis of TGF-,B1 expression. Immediately adjacent blocks of tumour were snap frozen in liquid nitrogen for subsequent immunohistochemical analysis using an antibody against the TGF-,ll latency-associated peptide (LAP). Antibodies A goat polyclonal antiserum, prepared against recombinant human TGF-,Bl latency-associated peptide rhLAP-TGF-#f, was obtained from R&D Systems (Oxon, UK). This antibody has been fully characterised and shown specifically to detect latent TGF-fil in immunohistochemical analysis (Barcellos-Hoff et al., 1994) . In direct ELISA and Western blot assays this antibody is specific for the LAP derived from the TGF-,B1 precursor but does not react with LAP from the TGF-,B2 precursor. The rhLAP-TGF-1l antibody was used to provide a differential in the immunodetection methods against active TGF-,iB. A chicken polyclonal antiserum prepared against recombinant human TGF-/1 was also obtained from R&D Systems. This antibody neutralises the biological activity of rhTGF-,1l, pTGF-,lB and pTGF-B1.2 and was used in our studies to detect the active form of TGF-,B1.
Materials and methods
Immunohistochemical analysis using an anti-TGF-f,1 antibody Sections (3 ,um) of formalin-fixed, paraffin-embedded samples were dewaxed in xylene and rehydrated through ethanol before the blocking of endogenous peroxidase activity with 3% v:v hydrogen peroxide in methanol for 15 min at room temperature (RT). The sections were washed in phosphatebuffered saline (PBS, pH 7.4) and treated with hyaluronidase (1 mg ml-' in 0.15 M sodium chloride; 0.1 M sodium acetate pH 5.5; Sigma, Poole, UK) for 30 min at RT. Following a 5 min wash in PBS the sections were incubated with 10% normal goat serum (NGS; Vector, Peterborough, UK) in PBS buffer for 1 h at RT to eliminate any non-specific staining before an overnight incubation at 4°C with a specific chicken anti-TGF-#l antibody (R&D Systems) diluted 1:250 in PBS buffer plus 1% NGS. In the negative controls, chicken serum in PBS buffer was substituted for the primary antibody. Following extensive washing in PBS, bound antibody was detected by the addition of a biotinylated goat anti-chicken antibody (Vector) diluted 1:400 in PBS buffer for 30 min at RT followed by exposure to preformed avidin-biotinylated peroxidase complex (ABC; Vector) for 30 min at RT. Sites of peroxidase reactivity were visualised with diaminobenzidine tetrahydrochloride (DAB) plus 0.2% (v.v) hydrogen peroxide followed by washing in tap water. Finally the sections were counterstained with 5% haematoxylin, dehydrated, cleared in histoclear and mounted in DPX mounting medium.
Immunohistochemistry using an anti-LAP-TGF-f3l antibody Sections (7 ,um) cut from snap-frozen material were fixed in 3.7% paraformaldehyde for 15 min and washed for 3 x 5 min with 0.1 M glycine in PBS. Endogenous peroxidase activity was blocked by incubating the slides in 3% v:v hydrogen peroxide in methanol for 10 min at RT. Following two 5 min washes in PBS, non-specific binding was blocked by incubating the sections with 0.5% casein in PBS for 1 h at RT. Excess solution was blotted from the sections which were then incubated overnight at 4°C with a goat anti-human LAP (TGF-,B1) antibody (R&D Systems) diluted 1:200 in PBS. In the negative controls blocking buffer substituted for the primary antibody. Following extensive washing in PBS, bound antibody was detected by the addition of a biotinylated rabbit anti-goat antiserum (Vector) diluted 1:250 in PBS for 30 min at RT followed by exposure to preformed ABC for 30 min at RT. Immunoreactivity was visualised as described above before the sections were dehydrated, cleared and mounted. Scoring Both immunocytochemical methods produced heterogeneous brown cytoplasmic staining. The stained sections were scored manually using a light microscope at x 400 magnification. The degree of staining for both immunohistochemical methods was divided into three grades; negative (-), positive (+) and strongly positive (+ +). Strong positivity was defined as TGF-fil staining in the majority (>80%) of cancer cells, which was more intense than that of stromal fibroblasts.
Statistical analysis
Correlations between TGF-f1 expression and the clinicopathological features of the tumours were tested using the chi-squared (X2) test. Overall survival curves were constructed by the method of Kaplan and Meier. We used a regression analysis to evaluate the effects of TGF-#l status on the incidence of recurrence and death from colorectal carcinoma while considering other prognostic factors.
Results
The relationship between clinicopathological findings and the expression of TGF-ll was determined in 72 colorectal tumours. Patient ages ranged from 32-92 years (mean, 70 years). There were more male than female patients and more rectal than colonic tumours in the study, although the ratio of male-female patients or rectal-colonic tumours was not significantly different between TGF-f expressors and nonexpressors (Table I) .
Immunohistochemical analysis with an anti-LAP-TGF-13I antibody All but ten of the tumours showed positive staining (+, + +) with the anti-LAP-TGF-,B1 antibody (Figure 1 ), which stained both epithelial and stromal cells. There was wide intertumoral heterogeneity, with an epithelial staining ranging from strongly positive (+ +) to negative (-). A similar variation was also seen in stromal cells. All tumours which were negative for LAP-TGF-fB1 showed no positive staining when using the specific anti-TGF-#1 antibody. The presence of LAP-TGF-#l, therefore, was not significantly correlated to any of the prognostic variables tested, i.e. histological grade, Dukes' stage or DNA ploidy. (Figure 2a ). Normal tissue adjacent to the tumour showed no similar staining patterns (Figure 2b ). There were no significant correlations between the expression of TGF-,B1 and the histological grade, curative/palliative resection and DNA ploidy (Tables III, IV and V). The TGF-31 status of Dukes' A and B tumours was identical, although significantly more Dukes' C and D tumours were TGF-fll-positive (Table II Figure 3a shows the Kaplan-Meier survival curves for these two groups of patients. In the patients considered to have had curative resections, the 3 year survival rate was 95% for the 13 patients with TGF-,B1-negative tumours, although there was no significant difference between these and the 18 patients with TGF-fll-positive tumours, whose 3 year survival rate was 75% (Figure 3b ). There was, however, a highly significant survival advantage for patients with TGF-f1l-negative tumours within the subgroup who received only a palliative resection. In these patients the 3-year survival rate was 60% in those with TGFfI-negative tumours compared with 5% for 24 patients with TGF-ll-positive tumours (X2=6.82, 1 d.f., P=0.009) ( Figure   3c ). Normal cells are induced to proliferate by the actions of multiple growth factors and it is the mutation or aberrant expression of components of the pathways by which these factors act that is thought to be involved in malignant transformation. Thus, measurement of the levels of growth factors, their receptors or the biochemical events that they activate in malignant tumours may provide important prognostic or diagnostic information. TGF-fI is a principal regulator in normal cell growth and function and also has an important role in angiogenesis, immunosuppression, formation of the extracellular matrix and tumorigenesis. Evidence would suggest that the control of tissue TGF-,B levels is of critical importance since transgenic mice overexpressing TGF-fI die in the perinatal period and 'knockout' mice lacking the gene for TGF-j1 die within a few weeks of birth (McCartney-Francis and Wahl, 1994) . Several studies indicate that tumour cells have an increased synthesis of TGF-f compared with their normal counterparts (Hirayama et al., 1992; LaRocca et al., 1992; Walker and Dearing, 1992) . This implies that high levels of TGF-,B favour tumour growth and progression.
In our panel of colorectal specimens we showed a significant positive correlation between TGF-,ll expression in the tumour epithelium and Dukes' stage. TGF-/1 The overall survival time of our panel of colorectal cancer patients was significantly shorter in those with TGF-llpositive tumours. This has also been shown in pancreatic tumours where a shorter post-operative survival time is seen in patients with TGF-13-positive tumours (Freiss et al.. 1993) . In our study. the relationship between tumour TGF-f1 positivity and poor prognosis was most significant in a subgroup of patients that had received only a palliative operation. A palliative resection of advanced colorectal cancer provides good relief of local symptoms but the outlook for these patients is poor and there is little evidence of a prolonged survival (Baigrie and Berry, 1994) . The ability to subdivide further the patients of a particularly poor prognosis group provides a basis for deciding which patients are most likely to benefit from more aggressive adjuvant treatment.
All the tumours except ten expressed the latent TGF-f1l as assessed by an anti-LAP-TGF-ll antibody. As the latent TGF-ll is the precursor of active TGF-#f. this Failure to activate secreted TGF-/31 is also unlikely as we were able to show that only the tumours expressing activated TGF-fIl had a poor prognosis. Furthermore. it has been shown that overproducers of either the active or the latent form of TGF-# are unresponsive even to exogenously added TGF-# in in vitro assays 
